Fusion Pharmaceuticals Inc. (FUSN) exited with a quarterly loss of $0.44 per share against the Zacks consensus estimate of a loss of $0.53. That compares to a loss of $0.63 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 16.98%. A quarter ago, this company was expected to post a loss of $0.50 per share when it actually produced a loss of $0.46, delivering an 8% surprise.
In the past four quarters, the company has exceeded consensus EPS estimates four times.
Fusion Pharmaceuticals Inc.
The sustainability of the immediate stock price movement based on recently released numbers and future earnings forecasts will primarily depend on management’s comments on the earnings call.
Shares of Fusion Pharmaceuticals Inc. are down about 47.5% year-to-date compared to the -13.1% decline in the S&P 500.
What’s next for Fusion Pharmaceuticals Inc.
While Fusion Pharmaceuticals Inc. has underperformed the market so far this year, the question on investors’ minds is: what’s next for the stock?
There are no easy answers to this key question, but one reliable metric that can help investors answer it is the company’s earnings outlook. This includes not only current consensus earnings expectations for the upcoming quarter(s), but also how those expectations have changed recently.
Empirical research shows a strong correlation between short-term stock movements and trends in earnings estimate revisions. Investors can track these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Prior to this earnings release, the trend of revisions to estimates for Fusion Pharmaceuticals Inc. Mixed. While the magnitude and direction of estimate revisions may change following the release of the company’s earnings report, the current situation translates into a No. 3 (hold) Zacks ranking for the stock. Thus, the shares should move in line with the market in the near future. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how the estimates for the next few quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.55 on $0.5 million in revenue for the upcoming quarter and -$2.12 on $1.19 million in revenue for the current fiscal year .
Investors should be aware that the outlook for the sector can also have a significant impact on stock performance. In terms of Zacks industry rankings, Medical – Drugs is currently in the top 36% of Zacks 250+ industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.
Another stock in the same sector, Radius Health (RDUS), has yet to report results for the quarter ending June 2022.
This biotech company is expected to post quarterly earnings of $0.08 per share in its next report, representing a year-over-year change of +122.9%. The consensus EPS estimate for the quarter remained unchanged for the past 30 days.
Radius Health revenue is expected to be $67.95 million, up 31.2% from the prior year quarter.
Want to know the #1 semiconductor stock for 2022?
Few people know how promising the semiconductor market is. Over the past two years, supply chain disruptions have caused shortages in several industries. The absence of a single semiconductor can halt all operations in some industries.
This year, the companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks reveals the best semiconductor stock for 2022. Find it in our new special report, A semiconductor stock is expected to earn the most.
Today it’s yours for free and without obligation.
>> Give me access to my free special report.
Click to get this free report
Fusion Pharmaceuticals Inc. (FUSN): Free Stock Analysis Report
Radius Health, Inc. (RDUS): Free Stock Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.